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The study determined the association of wrist circumference (WrC) and waist-to-height ratio (WHtR) with cardiometabolic risk
factors among diabetics in a Ghanaian population. This cross-sectional study involved 384 diabetic patients at Begoro District
Hospital, Ghana. Blood pressure, anthropometrics, and biochemical indices were measured. The overall prevalence of
dyslipidaemia, metabolic syndrome (MetS), and hypertension was 42.4%, 76.3%, and 39.8%, respectively. The optimum cut-off
range of WrC to identify individuals at increased cardiometabolic risk was 17.5 to –17.8 cm for men and 16.0 to 16.7 cm for
women while that of WHtR was 0.52 to 0.61 for men and 0.53 to 0.59 for women. WrC for women was a significant
independent predictor for MetS [aOR= 3.0 (1.39–6.72), p = 0 005] and systolic blood pressure [aOR= 2.08 (1.17–3.68), p = 0 012].
WHtR was a significant positive predictor for triglycerides [aOR= 3.23 (0.10–3.82), p = 0 001] for women. Using Framingham
risk scores, 61% of the subjects had elevated 10-year risk of developing cardiovascular diseases (CVDs), with no significant
difference in gender prevalence. WrC [aOR= 6.13 (0.34–111.4), p = 0 107] and WHtR [aOR= 2.52 (0.42–15.02), p = 0 309]
were associated with statistically insignificant increased odds of moderate-to-high risk of developing CVDs in 10 years. The
use of gender-specific cut-offs for WrC and WHtR may offer putative markers for early identification of CRFs.
1. Introduction
Diabetes mellitus (DM) is one of the major public health
problems worldwide, not only due to the increasing num-
ber of affected people, but also according to its relation
with disability and premature mortality and not neglect-
ing the costs involved in its treatment and prevention
[1, 2]. Africa alone accounted for 14 million diagnosed
cases of diabetes; as at 2015, Ghana recorded 266,200
cases with a prevalence rate of 1.9% in adults (20–79
years). About 4790 deaths recorded in the same year
aside the many undiagnosed cases in Africa, type II dia-
betes mellitus (T2DM) accounted for 90–95% of all diag-
nosed cases [3, 4]. The relationship between obesity and
diabetes has been well documented in the Ghanaian pop-
ulation [5, 6]. A study among urban and rural settlers in
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a Ghanaian population found an increased cardiometa-
bolic risk factors among urban settlers due to their
increased sedentary and unhealthy dietary habits [7]. In
sub-Saharan Africa, hypertension followed by obesity
was the commonly known cardiometabolic risk factors
associated with the general adult population [8]. Obesity
and overweight are associated with an increased cardio-
metabolic risk; however, this may vary significantly by
age, dietary habits, gender, and even among participants
with morbid obesity [9]. However, the argument about
the most effective anthropometric index associated with
cardiometabolic risk factors among diabetics remains unre-
solved. Cardiovascular disease (CVD) risk factors such as
obesity, hypertension, and dyslipidaemia are common in
patients with DM, placing them at increased risk for car-
diac events [10, 11]. In addition, many studies have found
biological mechanisms associated with DM that indepen-
dently increase the risk of CVD in diabetic patients
[10–12]. Body mass index (BMI) being the most studied
anthropometric index has been reported to be significantly
related to CVD risk factors as demonstrated by several
prospective and cross-sectional studies [13–15]. However,
there are cumulative doubts about its role in predicting
CVD risk factors. This has led to an increasing evidence
for abdominal obesity indices such as waist circumference
(WC), waist-to-hip ratio (WHR), and waist-to-height ratio
(WHtR) as predictors of CVD [16, 17]. In a study among
South African blacks, WHtR was found as a significant
predictor for all cardiometabolic risk components after 5
years in an adult population [18]. The application of
WHtR provides an alternative anthropometric index of
central obesity that avoids the limitations of WC because
the inclusion of height into the index enhances the avoid-
ance of any potential confounding of cardiometabolic risk
by height [19]. Previous studies have found similar WHtR
cut-offs for increased cardiometabolic risk among Cauca-
sian and Asian populations as well as men and women
[20]. WrC is a simple anthropometric tool for the measure-
ment of skeletal frame size. It has recently been suggested
in several studies to be associated with insulin resistance
in obese children and adults [21, 22], its consideration as
a measurement of peripheral fat distribution has attracted
much attention [23]. Moreover, it is an easy tool to detect
measures of skeletal frame size without being severely con-
founded by body fat variation [22].
Various other anthropometric indexes such as WC,
hip circumference (HC), and WHR have been used to
determine the index more closely related to cardiometa-
bolic risk factors among diabetics. To our knowledge, no
study has been done to determine the association of
WrC and WHtR with cardiometabolic risk factors among
diabetics in a Ghanaian population. In contrast to the rou-
tine management requirement, individual risk stratification
is highly recommended, and there is the need to elucidate
proper anthropometric measurement that defines individ-
uals who are at risk of cardiometabolic complications. To
fill this gap, the present study sought to determine the
association between WrC and WHtR with cardiometabolic
risk factors and ascertain WrC and WHtR predictive
values for cardiovascular risk burden using FS10 lipid risk
score system.
2. Methodology
2.1. Study Design and Setting. This was a cross-sectional
study conducted among diabetic patients attending Begoro
District Hospital diabetic clinic on a weekly basis. The dia-
betic clinic at Begoro District Hospital is the only hospital
in Fanteakwa North District in the Eastern Region of
Ghana that runs a diabetic clinic. Moreover, it is located
in Begoro and records attendance of 110,134 people per
annum from over 157 communities within the district. It
also serves as the main referral facility for Community
Health-based Planning Service (CHPS, i.e., a community
health officer-led program widely implemented across
Ghana, notable for its impact on under-5 and maternal
mortality [24]) centers, Clinics and Health centers in the
Fanteakwa District, and the adjoining districts. Therefore,
sampling was without bias but with fair distribution cov-
ering the ethnic groups, the majority being Akans and
Ga-dangmes within the district.
2.2. Study Population and Subject Selection. Using a non-
probability convenience sampling, a total of 384 diabetics
were recruited for the study. Selection of subject was done
using a structured questionnaire. Trained nurses were
placed at the Out-Patient Department (OPD) to adminis-
ter the questionnaires regarding lifestyle (including smok-
ing and drinking), medical history (including past illness
history and medication history), physiological conditions
(including pregnancy and fasting time), and sociodemo-
graphics, to all subjects during their health check-up.
The researcher verified the completion of each question-
naire prior to collection. Subjects with incomplete data as
well as those who were pregnant or had a chronic disease
that may affect the metabolic status or body composition
(e.g., thyroid or hypothalamic disease, chronic hepatitis,
and cirrhosis) were excluded from the study. The sample
used for the current analysis consisted of 147 men and
237 women. The protocol for the selection of subject is
shown in Figure 1.
2.3. Inclusion and Exclusion Criteria. All diabetic individuals
with complete data on sociodemographic and lifestyle char-
acteristics without any chronic disease reviewed from their
medical history were included in the study.
2.4. Sample Size Determination. A total of 384 diabetics were
recruited from an estimated diabetic population of 1870,
using a proportionate rate of 20.5%, confidence level of 95%
(z-score 1.96), and margin of error of 5%. Using Cochran’s
formula [25], the minimum size required was 300; however,
to accommodate a nonresponse rate of 10.0% and stronger
statistical power and effect size, the samples were projected
to 384 students.
2.5. Blood Pressure Measurement. Blood pressure (BP) was
recorded after 5 minutes of rest with the subject being in
the seated position using manual and an automated
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sphygmomanometer placed on the subject’s right arm.
This was measured three times, and the average reading
was recorded. Individuals were deemed hypertensive if
they were taking antihypertensive medications, if they
self-reported a diagnosis of hypertension, if their systolic
pressure was above 140mmHg, if their diastolic pressure
was above 90mmHg, or a combination of these features.
2.6. Anthropometric Measurements. Body weight, expressed
in 0.1 kg intervals, was measured at fasting state in the
morning using automated scale. Portable height rod stadi-
ometers were used for body height to the nearest centi-
meters. The subject stood straight, with feet placed
together and flat on the ground, heels, buttocks, and
scapulae against the vertical backboard, and arms loose
and relaxed with the palms facing medially. Their heads
were carefully positioned in the Frankfurt plane, with
the lower margins of the orbit in the same horizontal
plane as the upper margin of the external auditory mea-
tus. BMI was calculated as body weight divided by height
squared (kg/m2).
WrC was measured with subjects in a seated position
using a tape measure positioned over the Lister tubercle of
the distal radius and over the distal ulna. HC was measured
at the level of maximal gluteal protrusion and waist circum-
ference at the midpoint between the anterior superior iliac
crest and the lowest rib using a tape measure while the
subject stood with feet 25–30 cm apart. The tape measure
was placed directly on the skin. Patients were allowed to
breathe out normally, and measurements were taken. The
tape was held lightly so as not to compress the skin. WHtR
and WHR were calculated WC (cm) divided by Ht (cm)
and HC, respectively. Body adiposity index (BAI) was
calculated as the size of the hips compared to the patient’s
height [26].
BAI = HC cm ÷ height m 1 5 − 18 1
The conicity index (CI) was determined from the mea-
surements of weight, height, and waist circumference [27].
Conicity index = WC m
0 109 × weight kg /height m
2
Abdominal volume index (AVI) was derived from the
measurements of waist circumference (WC) and hip circum-
ferences (HC) [28].
AVI = 2 WC cm
2 + 0 7 WC cm −HC cm 2
1000 3
Visceral adiposity index (VAI) uses the study partici-
pant’s waist circumference (WC), BMI, triglyceride (TG),
and HDL-C levels [29].
Study population
All diabetic patients attending diabetic clinic, n = 1870
Selection criteria
Questionnaires administration to subject, n = 387
C
Medical and physiologicalASociodemographics
B
Lifestyle characteristics
Inclusion criteria
All subject with complete data, A + B + C (without pregnancy or
chronic disease recorded in C), n = 385
Exclusion criteria
Incomplete data in A or B or
both as well as pregnancy or chronic
disease recorded in C
Total subject analyze, N = 384
Yes
No
Figure 1: Flowchart of the protocol for the selection of subject.
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VAI for females = WC36 58 + 1 89 × BMI ×
TG
0 81
× 1 52HDL ,
VAI formales = WC39 68 + 1 88 × BMI ×
TG
1 03
× 1 31HDL
4
All measurement was done by two (2) health technicians,
one being the examiner and the other being the recorder.
2.7. Biochemical Analysis. Subjects fasted for a minimum of
12 hours and avoided a high-fat diet and alcohol consump-
tion for at least 24 h prior to phlebotomy. Fasting blood
glucose was measured using the One Touch glucometer and
recorded. A fasting venous blood sample was obtained
between 6:00 am and 11:00 am into a gel separator tube;
sample allowed to clot and centrifuged at 5000 rpm room
temperature for 5 minutes. Serum was then separated into
a plain tube and stored in a 4°C refrigerator prior to
analysis in the hospital laboratory. Clinical chemistry
workup included total cholesterol (TC), high-density lipo-
protein cholesterol (HDL-C), very-low-density lipoprotein
(VLDL-C), low-density lipoprotein (LDL-C), and triglycer-
ides (TG) using the COBAS INTEGRA® 400 plus automated
chemistry analyzer. Other parameters like the coronary risk
were calculated by dividing TC by HDL-C. A diagnosis of
MetS was defined as central obesity plus either dyslipidae-
mia and hypertension or raised plasma glucose as illus-
trated in Table 1. Cardiometabolic risk was defined as a
cluster of hypertension, metabolic syndrome, and an
enhanced waist circumference (above 102 cm in males and
88 cm in females) accompanied by the alterations in lipid
profile quoted above (HDL cholesterol below <1.03mmol/L
in males and <1.29mmol/L in females, and serum triglycer-
ides above ≥1.7mmol/L).
2.8. Statistical Analysis. All statistical analyses were per-
formed separately according to sex by using the Statistical
Package for Social Science (SPSS version 12.0). The basic
characteristics were presented by descriptive analysis as
means and standard deviations (SD) for continuous data
and as frequencies for categorical data. Comparisons
between men and women were made using independent
samples t-tests for continuous data and chi-square tests for
categorical data. Pearson’s correlation coefficients were
used to determine the correlation between anthropometric
indices and cardiometabolic risk factors. Receiver operating
characteristic (ROC) curves were used to demonstrate the
discriminatory ability of an anthropometric index over the
entire range of possible values in the detection of a cardio-
metabolic outcome as quantified by the area under the curve
(AUC). The optimal cut-off point for each anthropometric
variable in the prediction of a given cardiometabolic out-
come was established based on the highest combination
of sensitivity and specificity. p values of less than 0.05
were considered to indicate statistical significance.
3. Ethical Consideration
The investigations were approved by the Committee on
Human Research Publications and Ethics (CHRPE) at
School of Medical Sciences, Kwame Nkrumah University
of Science and Technology (KNUST), Kumasi, Ghana, in
collaboration with the management of Begoro District
Hospital. Participation was voluntary, and written informed
consent was obtained from each participant according to
Helsinki Declaration. Respondents were assured that the
information gathered was to be used strictly for research
and academic purpose only. In addition, respondents were
given the freedom to opt out at any time they thought they
could not continue with the study.
4. Results
The basic characteristics and prevalence of cardiometabolic
risk factors of the study sample are presented in Table 2.
The results found that mean age of men was significantly
higher compared to the age of the women (60.8± 11.5 versus
55.0± 13.3, p = 0 029). Male participant had significantly
larger wrist size than females (17.4± 0.8 versus 16.4± 1.0,
p value < 0.0001). The variation was also seen among
men and women where mean value for central adiposity
(WHR) was significantly higher among men (0.96± 0.07
versus 0.91± 0.06, p value = 0.002). However, significantly
higher TC and LDL-C levels were recorded in women
compared with men (7.2± 1.4 versus 5.9± 1.6 and 5.15±
1.35 versus 3.89± 1.42, respectively, p value < 0.0001). BAI
was also significantly higher in women compared to men
(32.8± 6.2 versus 27.6± 3.6, p value < 0.0001). The study
population was comparable in terms of cardiometabolic risk
prevalence and anthropometric parameters other than the
variations noted above (all p values > 0.05).
Table 3 illustrates the regression analysis of wrist
circumference for dyslipidaemia and haemodynamic param-
eters. Regarding women, WrC was observed to be the signif-
icant positive predictors for MetS [aOR=3.0 (1.39–6.72),
p = 0 005] and SBP [aOR=2.08 (1.17–3.68), p = 0 012]. The
coefficients of determination were 0.221 and 0.481, which
means WrC was significantly responsible for 22.1% and
48.1% for MetS and SBP. However, WrC was observed not
to be statistically significant predictors for dyslipidaemia
and haemodynamic indices in relation to men. WHtR was
observed to be the significant positive predictors for TG
[aOR=3.23 (0.10–3.82), p = 0 001] for women not men.
Table 4 depicts the AUC of each anthropometric index in
the prediction of multiple cardiometabolic risk among men
and women. Each index apart from visceral adiposity
index (VAI) was at its best in the prediction of MetS in
both sexes ranging from 0.68 to 1.00 at 95% confidence
interval, p values < 0.05. Among men and women, VAI was
the best predictor of dyslipidaemia (TG and low HDL-C).
The AUC of BAI in the prediction of TC was only significant
in male subjects. However, the AUC of WrC, WHtR, AVI,
VAI, CI, BAI, and BMI were best predictors of multiple
cardiometabolic risk factors (hypertension, MetS, and dysli-
pidaemia) among male and female subjects, p values < 0.05.
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The cut-off value of WrC predictive of cardiometabolic
risk factors was higher in male compared to that of female
(17.5 to 17.8 versus 16.0 to 16.7). However, that of BAI
was higher in women (30.5 to 32.8) than in men (24.2 to
29.5) in predicting cardiometabolic risk factors. Table 5
presents the cut-off values, sensitivities, and specificities
of anthropometric indices predictive of cardiometabolic
risk factors.
Multiple logistic analyses of lipid profile, haemodynamic
indices, and anthropometric indices for predicting incidence
Table 1: IDF definition of metabolic syndrome (IDF, 2006).
According to IDF, for a person to be defined as having cardiometabolic risk, the person must have a WC of >90 cm for men and >80 cm for
women or BMI> 30 kg/m2 and any two of the following.
Dyslipidaemia
Raised triglyceride, TG ≥1.7mmol/L or specific treatment for this lipid abnormality
Reduced HDL-C
<1.03mmol/L in males
<1.29mmol/L in females or specific treatment for this lipid abnormality
Hypertension
Systolic blood pressure ≥130mmHg
Diastolic blood pressure ≥85mmHg or treatment of previously diagnosed hypertension
Raised fasting plasma glucose (FPG)≥ 5.6mmol/L or previously diagnosed diabetes
Table 2: Descriptive of anthropometric indices, haemodynamic indices, and lipid parameters of study participants.
Variables Total (n = 384) Men (n = 147) Women (n = 237) p value
Age (years) 56.4± 13.1 60.8± 11.5 55.0± 13.3 0.029
Duration of diabetes (years) 9.3± 7.5 10.9± 8.0 8.8± 7.3 0.228
WrC (cm)a 16.5± 1.1 17.4± 0.8 16.4± 1.0 <0.0001
WC (cm)a 91.9± 10.7 92.4± 10.2 91.8± 10.9 0.794
WHRa 0.9± 0.1 1.0± 0.1 0.9± 0.1 0.002
WHtRa 0.6± 0.1 0.6± 0.1 0.6± 0.1 0.152
BMIa 26.2± 4.9 24.9± 3.4 26.6± 5.3 0.047
VAIa 3.4± 4.0 2.9± 2.9 3.6± 4.2 0.320
AVIa 17.2± 3.9 17.3± 3.7 17.2± 3.9 0.877
BAI (%)a 31.5± 6.1 27.6± 3.6 32.8± 6.2 <0001
CIa 1.3± 0.1 1.32± 0.1 1.30± 0.1 0.309
SBP (mmHg)a 133.3± 19.7 135.7± 16.2 132.6± 20.7 0.404
DBP (mmHg)a 82.0± 16.2 85.7± 10.0 80.8± 9.9 0.065
FBS (mmol/L)a 10.5± 4.2 10.8± 4.2 10.4± 4.2 0.700
TC (mmol/L)a 6.9± 1.6 5.9± 1.6 7.2± 1.4 <0.0001
TG (mmol/L)a 1.9± 0.9 1.9± 0.9 1.8± 0.9 0.972
HDL-C (mmol/L)a 1.2± 0.4 1.1± 0.4 1.3± 0.4 0.071
LDL-C (mmol/L)a 4.9± 1.5 3.9± 1.4 5.1± 1.4 <0.0001
VLDL (mmol/L)a 0.9± 0.4 0.8± 0.4 0.8± 0.4 0.972
Coronary riska 6.1± 2.7 5.8± 3.1 6.1± 2.5 0.591
High SBP, n (%)b 260 (67.8) 110 (75.0) 155 (65.6) 0.350
High DBP, n (%)b 153 (39.8) 68 (46.4) 89 (37.8) 0.414
High TG, n (%)b 178 (46.4) 68 (46.4) 110 (46.7) 0.982
Low HDL, n (%)b 205 (53.4) 58 (39.3) 137 (57.8) 0.087
MetS IDF, n (%)b 293 (76.3) 99 (64.3) 189 (80.0) 0.088
MetS WHO, n (%)b 289 (75.4) 101 (75.0) 179 (75.6) 0.952
MetS AACE, n (%)b 303 (78.8) 116 (78.6) 187 (78.9) 0.917
MetS NHLBI, n (%)b 296 (77.1) 105 (71.4) 187 (78.9) 0.412
MetS NCEP ATP III, n (%)b 296 (77.1) 105 (71.4) 187 (78.9) 0.412
All numbers are means ± standard deviation unless specified. at-tests. bChi-square tests. BMI: body mass index; WC: waist circumference; WHtR: waist-to-
height ratio; WHR: waist-to-hip ratio; BAI: body adiposity index; VAI: visceral adiposity index; CI: conicity index; AVI: abdominal volume index; MetS:
metabolic syndrome; FBG: fasting blood sugar; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglycerides; HDL-C:
high-density lipoprotein cholesterol. p < 0 05 = statistically significant.
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of 10-year CVD risk level among diabetic patients after
controlling for age duration of diabetes and history of
hypertension are shown in Tables 5 and 6. Subjects with poor
controlled of FBS are significantly more likely to develop
CVD [aOR=5.0 (1.09–22.82), p = 0 038]. Similarly, increased
likelihood was observed among patients with high TC
[aOR=2.65 (0.51–13.83)], TG [aOR=2.26 (0.41–12.28)],
LDL-C [aOR=2.0 (0.46–8.72)], and MetS [aOR=3.69
(0.98–13.86)] but was statistically not significant (p > 0 05).
The presence of MetS [aOR=4.53 (1.14–17.99), p = 0 031]
and diagnosed as hypertensive using SBP [aOR=68.2
(3.41–136.50), p = 0 0002] were associated with significant
increased risk of CVD.
As shown in Table 7, larger wrist circumference was
associated with increased odds [aOR=6.13 (0.34–111.4)] of
developing CVD in 10 years but was statistically not signifi-
cant (p > 0 05). Similarly, increased odds were observed in
other anthropometric indices for both moderated-to-high
risk of 10-year incidence of CVD but did not show any signif-
icant results (p > 0 05).
5. Discussion
Cardiometabolic risk has commonly been used to describe
the aggregate risk of developing cardiovascular disease.
Although there is a general agreement upon such a risk, dif-
ferences in the diagnosis of central obesity still exist [30]. In
this study, in addition to conventional indices of central obe-
sity, the recently introduced WrC and WHtR were included.
In this present study, WrC was significantly associated
with MetS and hypertension (using SBP> 140) in diabetic
female subjects, but no significant association was found in
male subject. Moreover, WrC was a significant predictor of
MetS and hypertension among female subjects even after
controlling for subject’s age, duration of diabetes, history of
hypertension, and FBS (glycaemic control) (Table 3). This
is inconsistent with the findings from a cross-sectional study
by Jahangiri et al. [21] among Iranian population. The study
found a significant positive association between WrC and
MetS in both genders. In women population, WrC is inde-
pendent from general and central obesity measures in the
prediction of cardiometabolic abnormalities [16]. This could
be expounded by the presence of “bone-fat-pancreas” axis
that regulates energy hemostasis and coordinates energy
partitioning between bone and adipose tissue and impacts
insulin sensitivity [23]. In another cross-sectional study by
Capizzi et al. [22] conducted among overweight and obese
children and adolescents to identify WrC as a marker for
insulin resistance, they found a significant positive associa-
tion between WrC, its bone component, and insulin resis-
tance, which is similar to our findings. Several other studies
have also presented results corroborating our findings in this
present study [23, 31]. WHtR was observed to be the signifi-
cant positive predictors for TG for women not men in this
study, which is in concordance with the findings from previ-
ous studies [18, 32, 33].
Differences between the two genders regarding the asso-
ciation between wrist circumference and cardiometabolic
risk factors occurrence could be due to the effects of sex ste-
roid hormones and their interaction with bone metabolism
and glucose homeostasis [21]. In a meta-analysis conducted
by Ma et al. [34] to evaluate association between bone
mineral density (BMD) and type 2 diabetes mellitus, they
concluded that overall individuals with T2DM have about
25–50% SD higher BMD compared to nondiabetic control
subjects. Physiologically, insulin has an anabolic effect on
Table 3: Cross-sectional association and predictability of baseline wrist circumference (WrC) for dyslipidaemia and haemodynamic indices.
Variable
Men Women
β (SE) R2 aOR (95% CI) p value β (SE) R2 aOR (95% CI) p value
WrC
MetS∗ 0.80 (0.67) 0.45 2.23 (0.60–8.28) 0.230 1.118 (0.402) 0.221 3.06 (1.39–6.72) 0.005
TCɵ 0.02 (0.54) 0.18 1.02 (0.35–2.95) 0.969 0.355 (0.424) 0.143 1.43 (0.63–3.28) 0.403
TGɵ 0.24 (0.54) 0.06 0.98 (0.36–2.68) 0.963 0.021 (0.210) 0.01 1.02 (0.67–1.54) 0.919
HDL-Cɵ 1.42 (0.81) 0.29 4.14 (0.85–20.24) 0.079 0.201 (0.239) 0.027 1.22 (0.77–1.95) 0.401
CR∗ 0.78 (0.72) 0.22 2.19 (0.54–8.90) 0.273 0.148 (0.217) 0.051 1.16 (0.76–1.77) 0.495
SBP∗ 0.42 (0.54) 0.09 1.52 (0.52–4.38) 0.436 0.730 (0.292) 0.481 2.08 (1.17–3.68) 0.012
DBP∗ 1.31 (0.71) 0.24 0.27 (0.07–1.08) 0.064 0.360 (0.244) 0.061 1.42 (0.89–2.31) 0.140
WHtR
MetS∗ 0.53 (0.81) 0.08 1.70 (0.40–2.01) 0.283 0.014 (0.102) 0.091 1.01 (0.43–1.07) 0.381
TCɵ 0.17 (0.90) 0.13 1.19 (0.30–2.91) 0.558 0.243 (0.183) 0.074 1.28 (0.39–2.18) 0.459
TGɵ 0.43 (0.81) 0.08 1.14 (0.31–2.22) 0.601 1.173 (0.228) 0.375 3.23 (0.10–3.82) 0.001
HDL-Cɵ −0.30 (0.81) 0.21 0.74 (0.20–8.34) 0.815 0.293 (0.197) 0.058 1.34 (0.05–1.99) 0.431
CR∗ 0.37 (0.75) 0.30 1.45 (0.17–2.83) 0.339 0.153 (0.216) 0.092 1.17 (0.53–1.95) 0.503
SBP∗ 0.31 (0.54) 0.05 1.36 (0.12–2.19) 0.407 0.527 (0.191) 0.329 1.69 (0.51–2.25) 0.425
DBP∗ 0.03 (0.21) 0.02 1.03 (0.18–1.25) 0.591 0.278 (0.37) 0.101 1.32 (0.51–1.72) 0.595
∗Adjusted for fasting blood glucose, duration of diabetes, history of hypertension, and age. ɵAdjusted for fasting blood glucose, duration of diabetes, and age.
CR: coronary risk.
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Table 4: AUC for various anthropometric indices and cardiometabolic risk factors in men and women.
(a)
Risk factor WrC VAI WHR WHtR
Men (n = 147)
Hypertension 0.59 (0.41–0.77)∗ 0.59 (0.37–0.81) 0.55 (0.34–0.76) 0.67 (0.47–0.86)∗
Mets IDF 0.69 (0.55–0.84)∗ 0.59 (0.39–0.79) 0.85 (0.72–0.98)∗ 0.99 (0.99–0.99)∗
High TC 0.57 (0.24–0.89) 0.50 (0.24–0.76) 0.54 (0.28–0.80) 0.57 (0.29–0.85)
High TG 0.59 (0.39–0.78) 0.94 (0.90–0.98)∗ 0.70 (0.49–0.90)∗ 0.53 (0.32–0.74)
Low HDL-C 0.70 (0.56–0.84)∗ 0.95 (0.95–0.95)∗ 0.50 (0.30–0.71) 0.57 (0.35–0.78)
Women (n = 237)
Hypertension 0.67 (0.67–0.67)∗ 0.53 (0.41, 0.65) 0.59 (0.47–0.71) 0.66 (0.57–0.79)∗
Mets IDF 0.73 (0.66–0.81)∗ 0.71 (0.58–0.84)∗ 0.68 (0.52–0.83)∗ 0.87 (0.77–0.97)∗
High TC 0.54 (0.48–0.61) 0.56 (0.43–0.69) 0.54 (0.38–0.55) 0.57 (0.44–0.71)
High TG 0.52 (0.52–0.52) 0.95 (0.92–0.99)∗ 0.51 (0.38–0.63) 0.53 (0.41–0.65)
Low HDL-C 0.60 (0.60–0.60)∗ 0.85 (0.78–0.93)∗ 0.60 (0.48–0.71) 0.52 (0.40–0.64)
(b)
Risk factor AVI CI BAI BMI
Men (n = 147)
Hypertension 0.66 (0.47–0.85)∗ 0.61 (0.41–0.82)∗ 0.72 (0.54–0.91)∗ 0.69 (0.50–0.88)∗
Mets IDF 1.00 (1.0-1.0)∗ 1.0 (1.0-1.0)∗ 0.78 (0.62–0.94)∗ 0.81 (0.66–0.96)∗
High TC 0.53 (0.28–0.77) 0.51 (0.26–0.74) 0.76 (0.54–0.98)∗ 0.58 (0.32–0.84)
High TG 0.56 (0.35–0.77) 0.57 (0.37–0.78) 0.55 (0.34–0.77) 0.50 (0.29–0.72)
Low HDL-C 0.54 (0.33–0.75) 0.56 (0.35–0.76) 0.66 (0.45–0.86) 0.54 (0.33–0.75)
Women (n = 237)
Hypertension 0.66 (0.54–0.77)∗ 0.61 (0.49–0.73)∗ 0.63 (0.51–0.74)∗ 0.68 (0.57–0.79)∗
Mets IDF 0.83 (0.71–0.96)∗ 0.68 (0.53–0.84)∗ 0.81 (0.69–0.94)∗ 0.88 (0.78–0.98)∗
High TC 0.58 (0.45–0.71) 0.59 (0.45–0.72) 0.57 (0.45–0.70) 0.58 (0.46–0.71)
High TG 0.54 (0.42–0.65) 0.52 (0.40–0.64) 0.58 (0.47–0.70) 0.56 (0.45–0.68)
Low HDL-C 0.50 (0.38–0.62) 0.51 (0.39–0.63) 0.51 (0.39–0.63) 0.50 (0.38–0.62)
Data are AUC (95% confidence interval). ∗ represents positive test if test variable < threshold. All values in bold are significant, p value <0.05.
Table 5: WrC and WHtR as a selected discriminator of cardiometabolic risk factors.
Discriminator AUC Cut-off Sensitivity, % Specificity, % Kappa
Women
WrC ∗ SBP 0.67 16.7 cm 43 84 0.05
WrC ∗ MetS 0.73 16.3 cm 61 72 0.23
WrC ∗ HDL-C 0.60 16.0 cm 39 82 0.04
WHtR ∗ SBP 0.67 0.55 80 53 0.24
WHtR ∗ MetS 0.99 0.53 90 78 0.58
Men 72
WrC ∗ MetS 0.69 17.8 cm 50 90 0.315
WrC ∗ HDL-C 0.70 17.5 cm 55 77 0.18
WrC ∗ MetS 0.73 16.3 cm 61 74 —
WHtR ∗ SBP 0.66 0.61 39 100 0.402
WHtR ∗ MetS 0.87 0.52 100 90 0.837
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bone due to its structural homology to IGF-1 by interacting
with the IGF-1 receptor, which is present on osteoblasts [34].
The current study identified the gender-stratified cut-off
points of potent anthropometric indices that proved to be
better predictors of cardiometabolic risk factors. The optimal
cut-off value of WrC to identify individuals at increased
cardiometabolic risk is between 17.5 and 17.8 cm for men
and 16.0 and 16.7 cm for women while that of WHtR was
between 0.52 and 0.61 for men and 0.53 and 0.59 for women.
Consistency in risk estimation using established cut-off was
poor to fair for WrC estimation; high systolic pressure, kappa
(0.05) for women; and metabolic syndrome, kappa (0.23) for
women and (0.32) for men. Consistency with WHtR was
good for SBP, kappa (0.24 and 0.40) for men and women,
respectively, to very good for metabolic syndrome, kappa
(0.58) for men and (0.84) for women, respectively. The
current study reported a 10-year risk of developing CVD
among diabetes patients and the plausible risk factors. Using
the Framingham risk scores, 61% of the subjects had an
elevated 10-year risk of developing cardiovascular diseases
(CVDs). Both male and female subjects showed descry prev-
alence of prejudicial cardiovascular risk and moderate to
higher risk of developing CVD in the future. Cohering the
results of this present study in part is a multicenter study in
Brazil among patients with type II diabetes by Gomes et al.
[35]. In another study among diabetic patients in Manipur,
Northeast India, Tungdim et al. [36] found similar results
Table 6: Multiple logistic analyses of lipid profile and
haemodynamic indices for predicting incidence of 10-year CVD
risk level among diabetic patients.
Variable
Moderate to high
aOR (95% CI) p value
TC
Low 1
High 3.0 (0.65–13.74) 0.157
TG
Low 1
High 4.73 (0.93–23.82) 0.060
HDL-C
High 1
Low 2.0 (0.39–10.16) 0.067
LDL-C
Low 1
High 4.13 (0.99–17.28) 0.052
CR 1
Normal 1
Risk 3.78 (0.75–19.06) 0.107
FBS
Poor control 2.79 (0.73–10.72) 0.038
Good control 1
SBP
Normal 1
Prehypertension 2.71 (0.59–12.31) 0.196
Hypertension 68.2 (3.41–136.5) 0.0002
MetS
No 1
Yes 4.53 (1.14–17.99) 0.031
Dyslipidaemia
No 1
Yes 2.92 (0.69–12.19) 0.142
Duration of disease
<5 1
05–10 0.52 (0.12–2.35) 0.398
>10 3.68 (0.36–37.92) 0.273
aOR: adjusted odds ratio; CI: confidence interval; FBG: fasting blood sugar;
SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total
cholesterol; TG: triglycerides; HDL-C: high-density cholesterol; MetS:
metabolic syndrome.
Table 7: Multiple logistic analyses of anthropometric indices for
predicting the incidence of 10-year CVD risk level among
diabetic patients.
Variables
Moderate to high
aOR (95% CI) p value
WrC
Normal 1
Larger 6.13 (0.34–111.4) 0.107
WC
Normal 1
Risk 0.95 (0.18–4.94) 0.951
BMI
Underweight —
Normal 1
Overweight 0.97 (0.25–3.70) 0.959
Obese 5.41 (0.27–104.7) 0.302
CI
Normal 1
Risk 1.01 (0.26–3.90) 0.987
VAI
Q1 1
Q2 2.43 (0.39–15.27) 0.344
Q3 2.29 (0.36–14.43) 0.379
Q4 3.57 (0.58–22.02) 0.170
WHR
Normal 1
Overweight 1.33 (0.10–17.99) 0.827
Obese 1.19 (0.12–11.41) 0.880
WHtR
Underweight —
Normal 1
Overweight 3.67 (0.27–49.29) 0.327
Obese 2.52 (0.42–15.02) 0.309
aOR: adjusted odds ratio; CI: confidence interval; BMI: body mass index;
WC: waist circumference; WHtR: waist-to-height ratio; WHR: waist-to-hip
ratio; BAI: body adiposity index; VAI: visceral adiposity index; CI: conicity
index; AVI: abdominal volume index.
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that corroborate our present finding. Several other studies
have reported a higher risk of CVD among women. Accumu-
lating evidence from recent findings has demonstrated
alterations in estrogen-related protective mechanism by
diabetes [21, 37]. This poses adverse changes in cardiovascu-
lar risk leading to enhanced atherogenesis in females [36]. In
a meta-analysis by Agatisa et al. [38] and Kanaya et al. [39]
among T2DM patients, they also reported that although the
odds of CVD mortality were higher among women than
men, the number of excess deaths attributable to diabetes
was higher among men after controlling for CVD risk. The
high incidence of moderate-to-high incidence of 10-year
cardiovascular among subjects could be explained in terms
of their lifestyle without exercise, poor glycaemic control
(74.6%), prevalence of hypertension (42.4%), high LDL
(80.5%), and MetS (76.3%).
Literature has provided several contradicting findings
concerned with detrimental effect of hyperglycaemia on car-
diovascular risk profile. High blood glucose level leads to
oxidative stress and mitochondrial overproduction of super-
oxide, which have been acknowledged in the pathogenesis of
diabetic micro- and macrovascular complications [40]. Regu-
lar physical exercise has been reported to be associated with
lower risk of cardiovascular morbidity and mortality, both
in the primary and secondary prevention [41], while eleva-
tion of small dense LDL particles and ApoB in type II diabe-
tes mellitus (T2DM) patients is a predictor of cardiovascular
risk [42]. The results of this present study found that larger
WrC was associated with increased odds of moderate and
high risk of developing CVD in 10 years (Table 5). In a
cohort study by Mohebi et al. [23], they reported that WrC
was independently associated with hypertension and CVD
outcome. WHtR was also a plausible risk marker for CVD
events with increasing odds of moderate and high 10-year
CVD incidence (Table 6). TheWrC was assumed to be a pos-
sible surrogate of body bone status and did not measure any
bone status measures; thus, we could not evaluate the true
predictive power of bone status in relation to CVD outcomes.
Notwithstanding that findings in this study are comparable
to reports from previous studies, the sample size was small,
and the use of nonprobability sampling approach may have
affected the statistical power and introduced sampling bias.
6. Conclusion
Using gender-specific cut-offs for WrC may offer putative
marker for early detection of cardiometabolic risk factors
among diabetic patients; therefore, being a simple and easy-
to-detect measure, WrC and WHtR could be regarded as a
new anthropometric assessment for prediction of cardiovas-
cular and metabolic complications. Moreover, considering
central and general obesity measurements, increasing wrist
circumference highlighted an independent risk for incident
cardiometabolic risk factors only among diabetic women.
Further study needs to be done to include measurements of
bone status and body fat stores to evaluate the true predictive
power of bone status in relation to cardiometabolic risk
outcome in a larger population.
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